The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Axsome Therapeutics Inc shares valued at $200,466 were purchased by Coleman Mark on Sep 08 ’25. At $127.28 per share, Coleman Mark acquired 1,575 shares. The insider’s holdings grew to 48,212 shares worth approximately $5.93 million following the completion of this transaction.
Also, Saad Mark E sold 9,127 shares, netting a total of over 1,141,514 in proceeds. Following the sale of shares at $125.07 each, the insider now holds 10,002 shares.
Before that, Saad Mark E had added 9,127 shares to its account. In a trade valued at $1,141,529, the Director bought Axsome Therapeutics Inc shares for $125.07 each.
As of June 03, 2025, Oppenheimer has initiated its “an Outperform” rating for AXSM. Earlier on April 07, 2025, Jefferies initiated its rating. Their recommendation was “a Buy” for AXSM stock.
Analyzing AXSM Stock Performance
On last trading session, Axsome Therapeutics Inc [NASDAQ: AXSM] plunged -0.93% to $122.96. The stock’s lowest price that day was $122.03, but it reached a high of $124.51 in the same session. During the last five days, there has been a drop of approximately -1.17%. Over the course of the year, Axsome Therapeutics Inc shares have jumped approximately 30.68%. Shares of the company reached a 52-week high of $139.13 on 02/21/25 and a 52-week low of $79.19 on 01/10/25.
Support And Resistance Levels for Axsome Therapeutics Inc (AXSM)
According to the 24-hour chart, there is a support level at 121.82, which, if violated, would cause prices to drop to 120.69. In the upper region, resistance lies at 124.30. The next price resistance is at 125.65. RSI (Relative Strength Index) is 60.39 on the 14-day chart, showing neutral technical sentiment.
Is Axsome Therapeutics Inc subject to short interest?
Stocks of Axsome Therapeutics Inc saw a sharp steep in short interest on 2025-08-29 dropping by -0.16 million shares to 3.51 million. Data from Yahoo Finance shows that the short interest on 2025-07-31 was 3.67 million shares. A decline of -4.68% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 6.0 of the overall float, the days-to-cover ratio (short ratio) decline to 6.0.
Which companies own the most shares of Axsome Therapeutics Inc (AXSM)?
In terms of Axsome Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 163 in the next 12 months, up nearly 31.32% from the previous closing price of $124.12. Analysts anticipate Axsome Therapeutics Inc stock to reach 216 by 2025, with the lowest price target being 162. In spite of this, 15 analysts ranked Axsome Therapeutics Inc stock as Buy at the end of 2025. On February 11, 2025, Deutsche Bank assigned a price target of “a Buy” to the stock and initiated coverage with a $176.
